May 28th, 2020 - In a randomized multicenter study, a strategy based on sentinel node biopsy (SNB) was equivalent to elective neck dissection (END) in the management of T1-T2N0 oral and oropharyngeal squamous cell carcinomas, with comparable 2-year neck recurrence-free survival (RFS) and lower morbidity in year 1 after surgery (Abstract 6501). Renaud Garrel, MD, of CHU Montpellier, France, presented the results...
May 28th, 2020 - Once-weekly selinexor, bortezomib, and dexamethasone (SVd) for relapsed/refractory multiple myeloma (MM) significantly improved progression-free survival (PFS) and overall response rate (ORR) when compared with twice-weekly bortezomib and dexamethasone (Vd), according to initial results from the phase III BOSTON trial (Abstract 8501).
May 28th, 2020 - CAR T-cell therapy with BCMA-targeting idecabtagene-vicleucel (ide-cel) resulted in deep and durable responses in heavily pretreated patients with relapsed/refractory multiple myeloma, according to phase II data from the KarMMa trial (Abstract 8503).
May 28th, 2020 - Teclistamab, a IgG-4 bispecific antibody targeting BCMA and CD3, appears to be safe in patients with relapsed or refractory multiple myeloma, according to phase I data presented during the ASCO20 Virtual Scientific Program (Abstract 100).
May 28th, 2020 - Donafenib significantly improved overall survival (OS) rates compared with sorafenib in patients with hepatocellular carcinoma (HCC) and did so with favorable safety and tolerability, according to a new study (Abstract 4506).
May 28th, 2020 - Muscle mass (quantity) is highly correlated with survival in hospitalized patients with advanced cancer, whereas muscle density (quality) is associated with patients’ symptoms, health care use, and survival, according to a group of researchers (Abstract 7006).
May 28th, 2020 - During the 2017 ASCO Annual Meeting, investigators of the ADJUVANT-CTONG 1104 trial first reported that postsurgical treatment with gefitinib conferred a significant 10.7-month improvement in disease-free survival (DFS) compared with standard doublet chemotherapy in patients with stage II-IIIA EGFR-positive non–small cell lung cancer (NSCLC), thus meeting the primary study endpoint (HR 0.60, 95...
May 28th, 2020 - Although HER-targeted therapy represents a standard of care for many HER2-positive malignancies, data supporting its benefit for patients with early-stage HER2-overexpressing esophageal adenocarcinoma are lacking. Results of the RTOG 1010 trial demonstrated that adding trastuzumab both before and after chemoradiotherapy and surgery did not significantly improve disease-free survival (DFS) beyon...
May 28th, 2020 - Prospective evaluation of nearly 13,000 individuals with stage III colon cancer found minimal difference in 5-year overall survival (OS) with 3 versus 6 months of adjuvant CAPOX or FOLFOX for the majority of patients, according to the final results of the International Duration Evaluation of Adjuvant Chemotherapy (IDEA) collaboration (Abstract 4004). In contrast, the shorter treatment course pr...
May 28th, 2020 - A new merit award memorializing a remarkable man’s lifetime mission of mentorship is honoring a particularly appropriate inaugural recipient—Sondos Zayed, MD, an early-career resident clinical investigator at Western University, Canada.
May 28th, 2020 - Approximately half of deaths can be avoided with the use of 3 years of adjuvant imatinib in the first decade after surgery for high-risk gastrointestinal stromal tumors (GIST), according to long-term data from the Scandinavian Sarcoma Group XVIII/German trial (Abstract 11503).
May 28th, 2020 - Exploratory analyses conducted in a subset of heavily pretreated patients with brain metastases enrolled on the HER2CLIMB trial found that tucatinib in combination with trastuzumab and capecitabine reduces the risk of intracranial (IC) progression and death in patients with HER2-positive metastatic breast cancer (MBC; Abstract 1005). Nancy U. Lin, MD, of Dana-Farber Cancer Institute, presented ...
May 28th, 2020 - The addition of stereotactic body radiation therapy (SBRT) to tyrosine kinase inhibitor (TKI) therapy yielded longer progression-free survival (PFS) and overall survival (OS) than TKI therapy alone in patients with EGFR-mutant oligometastatic non–small cell lung cancer (NSCLC), according to an interim analysis of an open-label phase III trial presented during the ASCO20 Virtual Scientific Progr...
May 28th, 2020 - When patients with acute myeloid leukemia (AML) undergo intensive chemotherapy treatment, their quality of life (QoL) and mood are negatively affected. Areej El-Jawahri, MD, of Massachusetts General Hospital, presented the results of a multicenter study conducted in patients with AML to determine if integrated palliative and oncology care could improve QoL and other important aspects of patient...
May 28th, 2020 - Findings from the primary analysis of the KAITLIN trial suggest that replacement of adjuvant taxane with trastuzumab emtansine (T-DM1) does not improve survival or safety for patients with HER2-positive early-stage breast cancer (Abstract 500). However, both treatments demonstrated outstanding long-term invasive disease–free survival (iDFS) in a high-risk population. Study author Nadia Harbeck,...
May 28th, 2020 - Imaging with 18F-DCFPyL–PET/CT was found to be diagnostically effective, often guiding a change in treatment plan, in men with biochemically relapsed prostate cancer, according to the results of the phase III CONDOR study presented during the ASCO20 Virtual Scientific Program (Abstract 5501).
May 28th, 2020 - Final survival results from three randomized, placebo-controlled trials, along with a safety analysis across all three, are helping to clarify the treatment landscape for nonmetastatic castration-resistant prostate cancer (nmCRPC). The results will be presented during the ASCO20 Virtual Scientific Program.
May 28th, 2020 - Two studies presented during the ASCO20 Virtual Scientific Program show the potential to de-escalate chemotherapy in the setting of dual HER2 blockade for patients with HER2-positive breast cancer.
May 28th, 2020 - Integrated oncogeriatric care led to improvements in health-related quality of life (HRQoL), unplanned hospital admissions, and treatment discontinuation in older people receiving systemic anticancer therapy, according to a study presented during the ASCO20 Virtual Scientific Program (Abstract 12011).
May 28th, 2020 - A randomized trial found that for patients with newly diagnosed Ewing’s sarcoma, a chemotherapy regimen consisting of vincristine, doxorubicin, and cyclophosphamide alternating with ifosfamide and etoposide (VDC/IE) offers better event-free survival (EFS) and overall survival (OS) than a regimen of vincristine, ifosfamide, doxorubicin, and etoposide (VIDE; Abstract 11500).